Related Experiment Video
Updated: Jul 28, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Response to nutritional and growth hormone treatment in progeria
J E Abdenur1, W T Brown, S Friedman
1Miami Children's Hospital, FL, USA.
Insights
Hutchinson-Gilford progeria syndrome (HGPS) is linked to elevated growth hormone (GH) and basal metabolic rate (BMR), causing failure to thrive. Treatments showed limited long-term benefits for growth and atherosclerosis.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Genetics
Background:
- Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder with unknown molecular causes.
- Patients exhibit failure to thrive (FTT), alopecia, scleroderma, joint stiffness, and severe atherosclerosis, with a median lifespan of 13 years.
- Cardiovascular complications are the primary cause of mortality in HGPS.
Purpose of the Study:
- To investigate the etiology of growth failure in HGPS through endocrine and metabolic studies.
- To evaluate the response to nutritional therapy (NT) and growth hormone (GH) treatment in HGPS patients.
Main Methods:
- Endocrine and metabolic assessments were conducted in five HGPS patients.
- Nutritional therapy (NT) and GH treatment were administered to three patients.
- Growth velocity (GV) and basal metabolic rate (BMR) were monitored.
Main Results:
- Elevated GH levels and an increased BMR were characteristic findings in HGPS, potentially explaining FTT.
- NT alone showed modest improvements in weight gain and GV.
- Combined NT and GH treatment increased GV and growth factors but paradoxically decreased BMR, with diminishing responses over time.
Conclusions:
- HGPS is associated with elevated GH and BMR, contributing to growth failure.
- While NT and GH offer temporary benefits, they do not prevent the progression of atherosclerosis.
- Further research is needed to understand the complex metabolic and endocrine aspects of HGPS.
Abstract:
Hutchinson-Gilford progeria syndrome (HGPS) is a rare condition with an unknown molecular defect. Patients with HGP progressively develop failure to thrive (FTT), alopecia, loss of subcutaneous fat, scleroderma, stiffening of various joints, and severe atherosclerosis. The median life span is 13 years, and the main cause of death is cardiovascular complications. There are few reports of endocrine and metabolic studies because of the rarity of this condition, and the response to long-term growth hormone (GH) treatment has not been described. We report the results of endocrine and metabolic studies performed to investigate the etiology of growth failure in five patients with HGP. Additionally, the response to nutritional therapy (NT) and GH treatment in three of these patients is presented. Our results suggest that elevated GH levels are characteristic of this disease and that an elevated basal metabolic rate (BMR) could be the cause of the FTT seen in HGP. Nonaggressive NT slightly improved weight gain and growth velocity (GV). Combined NT and GH treatment in three patients improved the GV, increased the levels of growth factors, and paradoxically resulted in decreased BMRs. However, the response to these therapies decreased over time and did not seem to prevent the progression of atherosclerotic disease.
Related Concept Videos
Nature and Nurture
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Hypoglycemia and Glucagon
Cellular Adaptation II: Hypertrophy
Cellular Adaptation III: Hyperplasia

